Edited by Raymond C Rowe - Senior Principal Scientist, AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, UK
Paul J Sheskey - Technical Services Leader, The Dow Chemical Company, Midland, MI, USA and Paul J Weller - Publisher - Science and Practice, Royal Pharmaceutical Society of Great Britain, London, UK
International Steering Committee
GE Amidon, Kalamazoo, MI, USA;
CG Cable, Edinburgh, UK;
WG Chambliss, University, MS, USA;
R Guest, Crawley, West Sussex, UK;
T Hadgett, Ware, Hertfordshire, UK;
JE Hogan, Sandwich, Kent, UK;
Y Kawashima, Gifu, Japan;
AH Kibbe, Wilkes-Barre, PA, USA;
MJ Lawrence, London, UK;
J Maclaine, Nottingham, UK;
RC Moreton, Toronto, Canada;
JM Newton, London, UK;
T Palmieri, Gainesville, FL, USA;
RC Rowe, Macclesfield, Cheshire, UK;
S Shah, Allegan, MI, USA;
PJ Sheskey, Midland, MI, USA;
A Wade, Bath, UK;
PJ Weller, London, UK
Pharmaceutical Press
